Crude Oil Moves Higher; Deere Cuts Profit Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2024
0mins
Source: Benzinga
- U.S. Stock Market: U.S. stocks traded mixed, with the Nasdaq Composite falling by 0.1% on Thursday. The Dow and S&P 500 also experienced slight declines.
- Top Headline - Deere & Co: Deere & Co reported positive second-quarter earnings but lowered its net income outlook for 2024.
- Equities Trading UP: BM Technologies, AST SpaceMobile, and TSR, Inc. saw significant increases in their share prices after reporting strong financial results or entering commercial agreements.
- Equities Trading DOWN: Eyenovia, Spire Global, and Omeros Corporation witnessed decreases in their stock prices following worse-than-expected financial results.
- Commodities and International Markets: Oil prices rose while gold prices fell. European shares were lower, and Asian markets closed higher. Japan's industrial production increased, but the economy shrank in the first quarter.
Analyst Views on OMER
Wall Street analysts forecast OMER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMER is 13.11 USD with a low forecast of 6.22 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 12.210
Low
6.22
Averages
13.11
High
20.00
Current: 12.210
Low
6.22
Averages
13.11
High
20.00
About OMER
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan diseases, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The Company's lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. Its lead phosphodiesterase 7 (PDE7) inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders. The Company also has preclinical programs, including an oncology platform for the development of novel therapeutics.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
